Patent ID: 8673850
Filing Date: 2014-03-18
Classification: A61K,A61P,C07K,G01N

Abstract:
1. A method of inhibiting PCSK9-induced LDLR degradation, or PCSK9-induced VLDLR degradation, PCSK9-induced ApoER2 degradation or PCSK9-induced CD81 degradation comprising contacting a cell expressing LDLR, VLDLR or ApoER2 with an inhibitor that is: a) a polypeptide comprising amino acids of full length AnxA2 isoform 1 or 2 (SEQ ID NO: 1 or 2) or 34-88 of AnxA2 (SEQ ID NO:3) or 34-97 of AnxA2 (SEQ ID NO:4) or 34-102 of AnxA2 (SEQ ID NO:5) or 34-108 of AnxA2 (SEQ ID NO:6) or 37-88 of AnxA2 (SEQ ID NO:7) or 37-97 of AnxA2 (SEQ ID NO:8) or 37-102 of AnxA2 (SEQ ID NO:9) or 37-108 of AnxA2 (SEQ ID NO:10) or 25-88 of AnxA2 (SEQ ID NO:11) or 25-97 of AnxA2 (SEQ ID NO:12) or 25-102 of AnxA2 (SEQ ID NO:13) or 25-108 of AnxA2 (SEQ ID NO:14) or 30-88 of AnxA2 (SEQ ID NO:15) or 30-97 of AnxA2 (SEQ ID NO:16) or 30-102 of AnxA2 (SEQ ID NO:17) or 30-108 of AnxA2 (SEQ ID NO:18) or 49-88 of AnxA2 (SEQ ID NO:19) or 49-97 of AnxA2 (SEQ ID NO:20) or 49-102 of AnxA2 (SEQ ID NO:21) or 49-108 of AnxA2 (SEQ ID NO:22); b) a functional derivative, analogue, or conjugate of a); c) 5-azacytidine or decitabine; d) a polypeptide ligand to PCSK9 C-terminal Cys-His-rich-domain (CHRD) e) a polypeptide ligand to PCSK9 CHRD's second subdomain module M2; f) p11; or g) a combination of any of the above.